禮來公司的口服GLP-1受體激動劑Foundayo（奧格列酮）在三個關鍵的第二型糖尿病試驗中均展現出更優的糖化血紅素A1C控制和體重減輕效果。
印第安納波利斯，2026年6月8日/PRNewswire/ -- Zepbound（替拉帕肽）的生產商禮來公司（NYSE：LLY）今日公佈了ACHIEVE項目中三項3期臨床試驗的詳細結果，這些…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
常見問題
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
